| 000 | 01874 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517181139.0 | ||
| 264 | 0 | _c20181211 | |
| 008 | 201812s 0 0 eng d | ||
| 022 | _a1875-9114 | ||
| 024 | 7 |
_a10.1002/phar.2046 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaura, Géric | |
| 245 | 0 | 0 |
_aComparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. _h[electronic resource] |
| 260 |
_bPharmacotherapy _c01 2018 |
||
| 300 |
_a6-18 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xcomplications |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDabigatran _xadministration & dosage |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 |
_aHospitalization _xstatistics & numerical data |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRivaroxaban _xadministration & dosage |
| 650 | 0 | 4 |
_aStroke _xprevention & control |
| 650 | 0 | 4 |
_aVitamin K _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAssessment of Medication Adherence |
| 700 | 1 | _aBillionnet, Cécile | |
| 700 | 1 | _aAlla, François | |
| 700 | 1 | _aGagne, Joshua J | |
| 700 | 1 | _aPariente, Antoine | |
| 773 | 0 |
_tPharmacotherapy _gvol. 38 _gno. 1 _gp. 6-18 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/phar.2046 _zAvailable from publisher's website |
| 999 |
_c27680910 _d27680910 |
||